Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	54.52T -24.5%
Revenue (ttm)	5.12T +50.3%
Net Income	1.98T +54.3%
EPS	45,556.40 +64.0%
Shares Out	46.24M
PE Ratio	28.40
Forward PE	27.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,032
Open	1,198,000
Previous Close	1,206,000
Day's Range	1,172,000 - 1,200,000
52-Week Range	1,165,000 - 1,987,000
Beta	0.19
Analysts	Buy
Price Target	1,899,600.15 (+61.12%)
Earnings Date	Oct 21, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,326
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2025, Samsung Biologics's revenue was 4.56 trillion, an increase of 30.31% compared to the previous year's 3.50 trillion. Earnings were 1.78 trillion, an increase of 64.71%.

Analyst Summary

According to 26 analysts, the average rating for 207940 stock is "Buy." The 12-month stock price target is ₩1,899,600, which is an increase of 61.12% from the latest price.

Price Target

₩1,899,600

(61.12% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 14, 2026

Data Sources Report a data error